A few days ago, EUROIMMUN (PerkinElmer) formally completed the acquisition of British diagnostic company Immunodiagnostic Systems (hereinafter referred to as IDS). In the future, IDS, as a new member of the PerkinElmer Group, will cooperate closely with EUROIMMUN in the fields of R&D, production, and sales.

IDS is a leading in vitro diagnostic company with more than 30 years of market experience. At present, IDS has about 300 employees worldwide, mainly dedicated to the research and development and promotion of diagnostic products in the fields of endocrinology, autoimmunity, infection and allergic diseases. At the same time, it has high-quality automation solutions and chemiluminescence immunoassay technology, which can be used for EUROIMMUN. The professional technology and product system form a useful supplement.

As a global leader in the field of autoimmune detection, EUROIMMUN has strong technical strength in the detection of autoimmune diseases, infectious diseases, and allergic diseases, as well as broad development potential in the field of molecular diagnostics. The addition of IDS will help enrich and strengthen EUROIMMUN's product portfolio and technical advantages in the field of related diseases, and will further consolidate EUROIMMUN's leading position in the diagnostic field.

IDS and EUROIMMUN have been partners for many years. This acquisition will encourage the two parties to carry out more in-depth cooperation, which is conducive to the further improvement of market expansion and professional service level, and continues to provide global customers with more complete and innovative diagnostic solutions. At the same time, it will also bring employees, customers, and partners More new opportunities and new values.